IntelGenx Technologies Corp. (IGXT) Analysts See $-0.04 EPS as of April, 4

IntelGenx Technologies Corp. (OTCMKTS:IGXT) Corporate Logo

IntelGenx Technologies Corp. (OTCMKTS:IGXT)’s quarterly earnings will be revealed on April, 4., Zacks reports. Analysts forecast $-0.04 EPS, which is $0.02 down or 100.00 % from 2018’s $-0.02 EPS. Last quarter $-0.04 EPS was reported. Analysts predicts 0.00 % EPS growth this quarter. IGXT is hitting $0.68 during the last trading session, after decreased 1.28%.Currently IntelGenx Technologies Corp. is after 0.00% change in last March 29, 2018. IGXT has also shares volume. The stock underperformed the S&P500 by 4.37%.

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market.The firm is worth $63.60 million. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines.Last it reported negative earnings. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat mild cognitive impairment and Alzheimer's disease.

For more IntelGenx Technologies Corp. (OTCMKTS:IGXT) news published briefly go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “CURE Pharmaceutical Readies $12 Million U.S. IPO – Seeking Alpha” published on December 06, 2018, “IntelGenx teams up with Tilray to develop oral film cannabis products – Seeking Alpha” on November 07, 2018, “IntelGenx: A Small Cap With A Big Pipeline In Cannabis, Alzheimer’s, And ED – Seeking Alpha” with a publish date: September 26, 2018, “IntelGenx and Tilray on go with Q4 launch of cannabis-infused oral film – Seeking Alpha” and the last “IntelGenx announces FDA’s acceptance of resubmission of NDA for RIZAPORT – Seeking Alpha” with publication date: November 20, 2018.

IntelGenx Technologies Corp. (OTCMKTS:IGXT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.